Clinical Trials

At RESTEM, we have developed stem cell technologies for the treatment of conditions in the area of regenerative medicine. We apply our stem cell genome technologies to the treatment of neurological, inflammatory, cardiovascular, and autoimmune conditions, that were once considered as irreversible. In recent years, we have advanced several programs and clinical trials to a broad network of collaborations, where we have worked with investigators with some of the leading institutions and scientists across the U.S. and Europe.

Rheumatoid Arthritis

ClinicalTrials.gov Identifier: NCT03691909
Status: Enrollment Complete. Follow up in progress.
Official Title: A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis

Parkinson's Disease

ClinicalTrials.gov Identifier: NCT04064983
Status: Enrollment Complete. Treatment in progress.

Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson’s Disease

Spinal Cord Injury


ClinicalTrials.gov Identifier: NCT04064957
Status: Enrollment Complete. Treatment in progress.

Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury

ClinicalTrials.gov Identifier: NCT03925649
Status: Enrollment Complete. Treatment in progress.
Collaborator: The University of Texas Health Science Center, Houston

Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

ClinicalTrials.gov Identifier: NCT04063215
Status: ON HOLD UNTIL FURTHER NOTICE
Due to the recent events of COVID-19, we have decided to delay this protocol until it is safe to resume.
Contact: Contact: Steven Kosmach, MSN 713-500-7329 Steven.Kosmach@uth.tmc.edu Contact: Joiya Arrington, MSN (713) 500-7395 Joiya.Arrington@uth.tmc.edu
Collaborator: The University of Texas Health Science Center, Houston

Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Cerebral Palsy

ClinicalTrials.gov Identifier: NCT04029896
Status: Enrollment Complete. Treatment in progress.

Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy.

Alzheimer's Disease

ClinicalTrials.gov Identifier: NCT04228666
Status: ON HOLD UNTIL FURTHER NOTICE
Due to the recent events of COVID-19, we have decided to delay this protocol until it is safe to resume.

Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer’s Disease.

COVID-19 (Allogenic Pre-Treatment)

ClinicalTrials.gov Identifier: NCT04348435
Status: Enrollment in Progress
Official Title: A Phase 2, Randomized, Placebo-Controlled, Clinical Trial to Assess Efficacy of Allogeneic HB-adMSCs to Provide Immune Support Against Coronavirus Disease.

This trial is open to:
Men, and women 18 years of age or older
Participant works in a capacity that is characterized as high-risk or very high-risk
High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19.
First responders, health care delivery and support staff (e.g., law enforcement, fire fighters, paramedics, doctors, nurses, and other hospital staff who must enter patients’ rooms) exposed to individuals potentially having COVID-19.
Mortuary workers involved in preparing (e.g., for burial or cremation) the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death
Very High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19 during specific medical, postmortem or laboratory procedures.
Health care workers (e.g., doctors, nurses, dentists, paramedics, emergency medical technicians) performing aerosol-generating procedures (e.g., intubation, cough induction procedures, bronchoscopies, some dental procedures and exams or invasive specimen collection) on known or suspected COVID-19 patients
Health care or laboratory personnel collecting or handling specimens from known or suspected COVID-19 patients (e.g., manipulating cultures from known or suspected COVID-19 patients)
Morgue workers performing autopsies, which generally involve aerosol-generating procedures, on the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death
If you meet any of these criteria and would like to paricipate in this trial, please apply here.

COVID-19 (Allogenic Treatment)


Clinicaltrials.gov Identifier : TBD
Enrollment: Will begin soon
Site: River Oaks Hopsital

Official Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19